Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36


Case Report: Imported Melioidosis from Goa, India, to Israel, 2018.

Tal BN, Daniel G, Shlomi A, Hanna L, Israeli M, Lazar S, Elia U, Israeli O, Beth-Din A, Bar-Haim E, Cohen-Gihon I, Zvi A, Cohen O, Theodor C.

Am J Trop Med Hyg. 2019 Jul 8. doi: 10.4269/ajtmh.19-0303. [Epub ahead of print]


Draft Genome Sequence of a Rare Israeli Clinical Isolate of Burkholderia pseudomallei.

Israeli O, Cohen-Gihon I, Brosh-Nissimov T, Zvi A, Beth-Din A, Shifman O, Israeli M, Elia U, Lazar S, Bar-Haim E, Cohen O, Chitlaru T.

Microbiol Resour Announc. 2019 May 9;8(19). pii: e00281-19. doi: 10.1128/MRA.00281-19.


Memory Inflation Drives Tissue-Resident Memory CD8+ T Cell Maintenance in the Lung After Intranasal Vaccination With Murine Cytomegalovirus.

Morabito KM, Ruckwardt TJ, Bar-Haim E, Nair D, Moin SM, Redwood AJ, Price DA, Graham BS.

Front Immunol. 2018 Aug 14;9:1861. doi: 10.3389/fimmu.2018.01861. eCollection 2018.


Protection of vaccinated mice against pneumonic tularemia is associated with an early memory sentinel-response in the lung.

Bar-On L, Cohen H, Elia U, Rotem S, Bercovich-Kinori A, Bar-Haim E, Chitlaru T, Cohen O.

Vaccine. 2017 Dec 15;35(50):7001-7009. doi: 10.1016/j.vaccine.2017.10.053. Epub 2017 Nov 6.


Novel CTL epitopes identified through a Y. pestis proteome-wide analysis in the search for vaccine candidates against plague.

Zvi A, Rotem S, Zauberman A, Elia U, Aftalion M, Bar-Haim E, Mamroud E, Cohen O.

Vaccine. 2017 Oct 20;35(44):5995-6006. doi: 10.1016/j.vaccine.2017.05.092. Epub 2017 Jun 9.


Neonatal mice possess two phenotypically and functionally distinct lung-migratory CD103+ dendritic cell populations following respiratory infection.

Ruckwardt TJ, Morabito KM, Bar-Haim E, Nair D, Graham BS.

Mucosal Immunol. 2018 Jan;11(1):186-198. doi: 10.1038/mi.2017.28. Epub 2017 Apr 5.


A novel live attenuated anthrax spore vaccine based on an acapsular Bacillus anthracis Sterne strain with mutations in the htrA, lef and cya genes.

Chitlaru T, Israeli M, Rotem S, Elia U, Bar-Haim E, Ehrlich S, Cohen O, Shafferman A.

Vaccine. 2017 Oct 20;35(44):6030-6040. doi: 10.1016/j.vaccine.2017.03.033. Epub 2017 Mar 23.


Toxins as biological weapons for terror-characteristics, challenges and medical countermeasures: a mini-review.

Berger T, Eisenkraft A, Bar-Haim E, Kassirer M, Aran AA, Fogel I.

Disaster Mil Med. 2016 Apr 29;2:7. doi: 10.1186/s40696-016-0017-4. eCollection 2016. Review.


A Simple Luminescent Adenylate-Cyclase Functional Assay for Evaluation of Bacillus anthracis Edema Factor Activity.

Israeli M, Rotem S, Elia U, Bar-Haim E, Cohen O, Chitlaru T.

Toxins (Basel). 2016 Aug 18;8(8). pii: E243. doi: 10.3390/toxins8080243.


Next-Generation Bacillus anthracis Live Attenuated Spore Vaccine Based on the htrA(-) (High Temperature Requirement A) Sterne Strain.

Chitlaru T, Israeli M, Bar-Haim E, Elia U, Rotem S, Ehrlich S, Cohen O, Shafferman A.

Sci Rep. 2016 Jan 6;6:18908. doi: 10.1038/srep18908.


CD8+ TCR transgenic strains expressing public versus private TCR targeting the respiratory syncytial virus K(d)M2(82-90) epitope demonstrate similar functional profiles.

Bar-Haim E, Erez N, Malloy AM, Graham BS, Ruckwardt TJ.

PLoS One. 2014 Jun 4;9(6):e99249. doi: 10.1371/journal.pone.0099249. eCollection 2014.


Protective immunity against lethal F. tularensis holarctica LVS provided by vaccination with selected novel CD8+ T cell epitopes.

Rotem S, Cohen O, Bar-Haim E, Bar-On L, Ehrlich S, Shafferman A.

PLoS One. 2014 Jan 6;9(1):e85215. doi: 10.1371/journal.pone.0085215. eCollection 2014.


YopP-expressing variant of Y. pestis activates a potent innate immune response affording cross-protection against yersiniosis and tularemia [corrected].

Zauberman A, Flashner Y, Levy Y, Vagima Y, Tidhar A, Cohen O, Bar-Haim E, Gur D, Aftalion M, Halperin G, Shafferman A, Mamroud E.

PLoS One. 2013 Dec 16;8(12):e83560. doi: 10.1371/journal.pone.0083560. eCollection 2013. Erratum in: PLoS One. 2014;9(1). doi:10.1371/annotation/0ec1f217-4e7a-4dee-9a71-1076a3ac73f1.


Consequences of delayed ciprofloxacin and doxycycline treatment regimens against Francisella tularensis airway infection.

Rotem S, Bar-Haim E, Cohen H, Elia U, Ber R, Shafferman A, Cohen O.

Antimicrob Agents Chemother. 2012 Oct;56(10):5406-8. doi: 10.1128/AAC.01104-12. Epub 2012 Jul 30.


Whole-genome immunoinformatic analysis of F. tularensis: predicted CTL epitopes clustered in hotspots are prone to elicit a T-cell response.

Zvi A, Rotem S, Bar-Haim E, Cohen O, Shafferman A.

PLoS One. 2011;6(5):e20050. doi: 10.1371/journal.pone.0020050. Epub 2011 May 20.


The involvement of IL-17A in the murine response to sub-lethal inhalational infection with Francisella tularensis.

Markel G, Bar-Haim E, Zahavy E, Cohen H, Cohen O, Shafferman A, Velan B.

PLoS One. 2010 Jun 18;5(6):e11176. doi: 10.1371/journal.pone.0011176.


Yersinia pestis endowed with increased cytotoxicity is avirulent in a bubonic plague model and induces rapid protection against pneumonic plague.

Zauberman A, Tidhar A, Levy Y, Bar-Haim E, Halperin G, Flashner Y, Cohen S, Shafferman A, Mamroud E.

PLoS One. 2009 Jun 16;4(6):e5938. doi: 10.1371/journal.pone.0005938.


Interrelationship between dendritic cell trafficking and Francisella tularensis dissemination following airway infection.

Bar-Haim E, Gat O, Markel G, Cohen H, Shafferman A, Velan B.

PLoS Pathog. 2008 Nov;4(11):e1000211. doi: 10.1371/journal.ppat.1000211. Epub 2008 Nov 21.


'1-8 interferon inducible gene family': putative colon carcinoma-associated antigens.

Tirosh B, Daniel-Carmi V, Carmon L, Paz A, Lugassy G, Vadai E, Machlenkin A, Bar-Haim E, Do MS, Ahn IS, Fridkin M, Tzehoval E, Eisenbach L.

Br J Cancer. 2007 Dec 17;97(12):1655-63. Epub 2007 Dec 11.


Discordance in the effects of Yersinia pestis on the dendritic cell functions manifested by induction of maturation and paralysis of migration.

Velan B, Bar-Haim E, Zauberman A, Mamroud E, Shafferman A, Cohen S.

Infect Immun. 2006 Nov;74(11):6365-76. Epub 2006 Aug 21.


Efficacious, nontoxigenic Bacillus anthracis spore vaccines based on strains expressing mutant variants of lethal toxin components.

Mendelson I, Gat O, Aloni-Grinstein R, Altboum Z, Inbar I, Kronman C, Bar-Haim E, Cohen S, Velan B, Shafferman A.

Vaccine. 2005 Dec 1;23(48-49):5688-97. Epub 2005 Feb 5.


Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.

Machlenkin A, Paz A, Bar Haim E, Goldberger O, Finkel E, Tirosh B, Volovitz I, Vadai E, Lugassy G, Cytron S, Lemonnier F, Tzehoval E, Eisenbach L.

Cancer Res. 2005 Jul 15;65(14):6435-42.


Combined dendritic cell cryotherapy of tumor induces systemic antimetastatic immunity.

Machlenkin A, Goldberger O, Tirosh B, Paz A, Volovitz I, Bar-Haim E, Lee SH, Vadai E, Tzehoval E, Eisenbach L.

Clin Cancer Res. 2005 Jul 1;11(13):4955-61.


[Laboratory methods for detection and identification of biological pathogens].

Bar-Haim E, Aran A, Marcus N, Finkelstein A, Amsalem Y, Yehezkeli Y.

Harefuah. 2005 May;144(5):341-6, 382. Review. Hebrew.


MAGE-A8 overexpression in transitional cell carcinoma of the bladder: identification of two tumour-associated antigen peptides.

Bar-Haim E, Paz A, Machlenkin A, Hazzan D, Tirosh B, Carmon L, Brenner B, Vadai E, Mor O, Stein A, Lemonnier FA, Tzehoval E, Eisenbach L.

Br J Cancer. 2004 Jul 19;91(2):398-407.


Non-replicating mucosal and systemic vaccines: quantitative and qualitative differences in the Ag-specific CD8(+) T cell population in different tissues.

Qimron U, Paul L, Bar-Haim E, Bloushtain N, Eisenbach L, Staats HF, Porgador A.

Vaccine. 2004 Mar 29;22(11-12):1390-4.


Expression of FasL by tumor cells does not abrogate anti-tumor CTL function.

Lee SH, Bar-Haim E, Goldberger O, Reich-Zeliger S, Vadai E, Tzehoval E, Eisenbach L.

Immunol Lett. 2004 Feb 15;91(2-3):119-26.


In vivo rejection of tumor cells dependent on CD8 cells that kill independently of perforin and FasL.

Lee SH, Bar-Haim E, Machlenkin A, Goldberger O, Volovitz I, Vadai E, Tzehoval E, Eisenbach L.

Cancer Gene Ther. 2004 Mar;11(3):237-48.


Characterization of novel breast carcinoma-associated BA46-derived peptides in HLA-A2.1/D(b)-beta2m transgenic mice.

Carmon L, Bobilev-Priel I, Brenner B, Bobilev D, Paz A, Bar-Haim E, Tirosh B, Klein T, Fridkin M, Lemonnier F, Tzehoval E, Eisenbach L.

J Clin Invest. 2002 Aug;110(4):453-62.


CD66a interactions between human melanoma and NK cells: a novel class I MHC-independent inhibitory mechanism of cytotoxicity.

Markel G, Lieberman N, Katz G, Arnon TI, Lotem M, Drize O, Blumberg RS, Bar-Haim E, Mader R, Eisenbach L, Mandelboim O.

J Immunol. 2002 Mar 15;168(6):2803-10.


Second neoplasms in patients with Merkel cell carcinoma.

Brenner B, Sulkes A, Rakowsky E, Feinmesser M, Yukelson A, Bar-Haim E, Katz A, Idelevich E, Neuman A, Barhana M, Fenig E.

Cancer. 2001 Apr 1;91(7):1358-62.


Antitumor vaccination using peptide based vaccines.

Eisenbach L, Bar-Haim E, El-Shami K.

Immunol Lett. 2000 Sep 15;74(1):27-34. Review.


Anti-tumor vaccination in heterozygous congenic F1 mice: presentation of tumor-associated antigen by the two parental class I alleles.

Carmon L, Tzehoval E, Tirosh B, el-Shami KM, Bar-Haim E, Vadai E, Feldman M, Eisenbach L.

J Immunother. 2000 May-Jun;23(3):344-52.


Immunogenicity of H-2Kb-low affinity, high affinity, and covalently-bound peptides in anti-tumor vaccination.

Tirosh B, el-Shami K, Vaisman N, Carmon L, Bar-Haim E, Vadai E, Feldman M, Fridkin M, Eisenbach L.

Immunol Lett. 1999 Oct 1;70(1):21-8.


MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope.

el-Shami K, Tirosh B, Bar-Haim E, Carmon L, Vadai E, Fridkin M, Feldman M, Eisenbach L.

Eur J Immunol. 1999 Oct;29(10):3295-301.


Identification of shared tumor-associated antigen peptides between two spontaneous lung carcinomas.

Mandelboim O, Bar-Haim E, Vadai E, Fridkin M, Eisenbach L.

J Immunol. 1997 Dec 15;159(12):6030-6.


Supplemental Content

Loading ...
Support Center